ProMIS Neurosciences Strengthens Board with Ally Bridge Group's Slanix Paul Alex

ProMIS Neurosciences has appointed Slanix Paul Alex to its Board of Directors, aiming to enhance its position in the competitive biotechnology sector focused on neurodegenerative disorders like Alzheimers disease.

• ProMIS Neurosciences, a public company specializing in biotechnology for neurodegenerative disorders, appointed Slanix Paul Alex to its Board of Directors on Wednesday.
• Slanix Paul Alex is the President and Portfolio Manager for Ally Bridge Groups Public Equity strategy, bringing extensive finance and health care expertise to the company.
• The appointment comes as ProMISs stock has faced an 8% decline over the past week, indicating potential market challenges in the biotechnology sector.